Figures & data
Table 1 Ongoing Studies Utilizing Tiragolumab
Table 2 Comparison of IMpower133, CASPIAN and SKYSCRAPER-02 Endpoints
Lung Cancer: Targets and Therapy
Volume 14, 2023 - Issue
REVIEW
Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno
, 
&
Sai-Hong Ignatius Ou1 Department of Medicine, University of California Irvine School of Medicine, Orange, CA, USA;2 Chao Family Comprehensive Cancer Center, Orange, CA, USAhttps://orcid.org/0000-0002-1764-4975View further author information
https://orcid.org/0000-0002-1764-4975View further author information & Misako Nagasaka1 Department of Medicine, University of California Irvine School of Medicine, Orange, CA, USA;2 Chao Family Comprehensive Cancer Center, Orange, CA, USA;3 St. Marianna University School of Medicine, Kawasaki, JapanCorrespondence[email protected]
https://orcid.org/0000-0001-5308-615XView further author information
https://orcid.org/0000-0001-5308-615XView further author information